Loading stock data…
$0.54-0.02 (-3.53%)
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications.
Outlook Therapeutics, Inc. in the Healthcare sector is trading at $0.54 with a market capitalization of $156M. Wall Street consensus targets $5.03 (4 analysts), implying a +823.9% move over the next 12 months. The stock is currently near its 52-week low of $0.16, remaining 20.0% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $8,700↓ | $127,439↑ | -$1.21M↓ | -$91,787↓ | $1.51M |
| Gross Profit | -$8,265↑ | -$21,888↑ | -$1.24M↓ | -$1.01M↓ | $1.07M |
| Operating Income | -$10.81M↑ | -$14.03M↓ | -$13.48M↑ | -$17.31M↓ | -$15.75M |
| Net Income | -$20.32M↓ | -$4.45M↑ | -$23.06M↓ | -$13.29M↑ | -$20.15M |
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product ...